|1.||Surolia, Avadhesha: 3 articles (05/2007 - 01/2004)|
|2.||Surolia, Namita: 3 articles (05/2007 - 01/2004)|
|3.||Sacchettini, James C: 2 articles (04/2015 - 04/2006)|
|4.||Bommineni, Gopal R: 2 articles (06/2014 - 01/2013)|
|5.||Cummings, Jason E: 2 articles (06/2014 - 01/2013)|
|6.||Slayden, Richard A: 2 articles (06/2014 - 01/2013)|
|7.||Tonge, Peter J: 2 articles (06/2014 - 01/2013)|
|8.||Sharma, Shailendra Kumar: 2 articles (05/2007 - 06/2006)|
|9.||Umei, Tomohiro: 1 article (04/2015)|
|10.||Aoki, Shunsuke: 1 article (04/2015)|
01/01/2013 - "The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection."
01/22/2015 - "Mycobacterial enoyl acyl carrier protein reductase (InhA) is a clinically validated target for the treatment of tuberculosis infections, a disease that still causes the death of at least a million people annually. "
04/15/2014 - "The findings of this study not only validated Cryptosporidium ACS (and related acyl-[acyl-carrier-protein]-ligases) as pharmacological targets but also indicate that triacsin C and analogues can be explored as potential new therapeutics against the virtually untreatable cryptosporidial infection in immunocompromised patients."
06/06/2014 - "CG400549, a Staphylococcus-specific 2-pyridone compound that inhibits the enoyl-acyl carrier protein reductase (FabI), has recently been shown to possess human efficacy for the treatment of methicillin-resistant Staphylococcus aureus infections, which constitute a serious threat to human health. "
04/04/2006 - "Inhibition of the enzyme Mycobacterium tuberculosis InhA (enoyl-acyl carrier protein reductase) due to formation of an isonicotinoyl-NAD adduct (IN-NAD) from isoniazid (INH) and nicotinamide adenine dinucleotide cofactor is considered central to the mode of action of INH, a first-line treatment for tuberculosis infection. "
04/13/2015 - "tuberculosis) enoyl-acyl carrier protein reductase (mtInhA) is an attractive enzyme and a thoroughly studied target for tuberculosis therapy. "
01/22/2015 - "Design, synthesis, and evaluation of new thiadiazole-based direct inhibitors of enoyl acyl carrier protein reductase (InhA) for the treatment of tuberculosis."
10/30/2014 - "Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis."
03/20/2007 - "tuberculosis genes encoding distinct beta-ketoacyl- acyl carrier protein synthases involved in mycolic acid synthesis, results in loss of acid-fast staining. "
06/06/2006 - "tuberculosis, expression of one gene from this pathway, lipB, encoding for octanoyl-[acyl carrier protein]-protein acyltransferase is considerably up-regulated, thus making it a potential target in the search for novel antiinfectives against tuberculosis. "
|3.||Dehydration (Water Stress)
03/26/2014 - "Here we demonstrate that this TE catalyzes the dehydration of the polyketide intermediate to yield a cis-double bond and a mutated KS transfers the nascent polyketide chain with only a cis-double bond to the downstream acyl carrier protein. "
08/12/2005 - "In bacteria, beta-hydroxyacyl-acyl carrier protein (ACP) dehydratase (FabZ) is a potent enzyme in fatty acid biosynthesis and catalyzes the dehydration of beta-hydroxyacyl-ACP to trans-2-acyl-ACP. "
01/01/2004 - "In this cycle, the dehydration of the beta-hydroxyacyl acyl carrier protein is catalyzed by FabZ. "
11/22/2002 - "The double bond is introduced into the growing acyl chain by FabA, an enzyme capable of both the dehydration of beta-hydroxydecanoyl-acyl carrier protein (ACP) to trans-2-decenoyl-ACP, and the isomerization of trans-2 to cis-3-decenoyl-ACP. "
05/14/2010 - "Functional investigation of the proposed dehydratase domain of ATX, a 6-methylsalicylic acid synthase from Aspergillus terreus, revealed that the domain is not involved in dehydration of the beta-hydroxytriketide intermediate tethered on the acyl carrier protein but catalyzes thioester hydrolysis to release the product from the acyl carrier protein. "
11/05/1991 - "We recently reported the expression and characterization of the acyl carrier protein and thioesterase domains of the chicken liver fatty acid synthase in Escherichia coli. "
04/01/1989 - "The acyl carrier protein domain of the chicken liver fatty acid synthase has been isolated after tryptic treatment of the synthase. "
11/10/1974 - "Dissociation of the acyl carrier protein subunit from dog liver fatty acid synthetase complex."
09/09/1974 - "The isolation of acyl carrier protein from the pigeon liver fatty acid synthetase complex1 II."
09/14/1982 - "Isolation and characterization of an acyl carrier protein from pigeon liver fatty acid synthetase by controlled proteolysis with elastase."
06/06/2006 - "Acyl Carrier Protein (ACP) from the malaria parasite, Plasmodium falciparum (PfACP) in its holo form is found to exist in two conformational states in solution. "
11/01/2012 - "Enoyl-acyl carrier protein reductase (ENR) is a crucial enzyme in the type II fatty acid synthesis pathway of many pathogens such as Plasmodium falciparum, the etiological agent of the most severe form of malaria. "
05/31/2007 - "Enoyl acyl carrier protein (ACP) reductase, one of the enzymes of the type II fatty acid biosynthesis pathway, has been established as a promising target for the development of new drugs for malaria. "
|8.||Staphylococcal Protein A (A, Protein)
|9.||Proteins (Proteins, Gene)
|10.||Pancreatic Elastase (Elastase)